This collaboration supports the ‘Green Navy’ initiative, aiming for a sustainable and environmentally responsible future ...
Emerging companies in synthetic biology and cell therapy are disrupting traditional healthcare solutions, while agricultural biotechnology is delivering disease-free banana varieties and herbicide ...
Robson Green may live in a ferryman's cottage in Hexham ... Charles similarly loves meals made with homegrown ingredients. The royal bought Highgrove House in 1980, and he first lived there ...
A busy working chapel, the Chapel Royal holds regular services which are open to the general public, as well as hosting some unique Royal services. If you would like to attend a service, click on ...
(Instagram) After Sophie Molineux was ruled out of the Women's Premier League (WPL) 2025, Royal Challengers Bengaluru ... High-Performance Development, Liz Green said. "Sophie’s had excellent ...
They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...
Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...
The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers.
After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) candidate from a clinical hold. When Amylyx had asked the FDA to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback